secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001493152-23-016285
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncocyte Q1 revenue down 50% to $0.7M; CFO Anish John to leave June 15
----------------------------------------------------------------------

- Revenue $0.7M, down 50% YoY; net operating income $2.9M vs loss of $9.4M.
- CFO Anish John departing June 15, 2023; no disagreements; search for replacement.
- Completed $13.86M equity raise in April from common stock sale.
- R&D expenses $2.8M (-45% YoY); G&A $3.7M (-35%); S&M $1.2M (-63%).
- Sold 70% of Razor Genomics; transitioning to capital-light kitted product model.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000149315223016285/0001493152-23-016285-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000149315223016285/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-016285

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer